• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Hemgenix (etranacogene dezaparvovec-drlb)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Hemgenix (etranacogene dezaparvovec-drlb)

  • Profile

Profile

Contact Information

Contact: CSL
Website: https://www.hemgenix.com/

Currently Enrolling Trials

    Show More

    General Information

    Hemgenix (etranacogene dezaparvovec-drlb) is an adeno-associated virus vector-based gene therapy.

    Hemgenix is specifically indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:

    • Currently use Factor IX prophylaxis therapy, or
    • Have current or historical life-threatening hemorrhage, or
    • Have repeated, serious spontaneous bleeding episodes

    Hemgenix is supplied as an injection for single-use intravenous administration. Dosing and Administration is as follows:

    • Perform baseline testing to select patients, including testing for Factor IX inhibitor presence and liver health tests.
    • The recommended dose of Hemgenix is 2 x 1013 genome copies (gc) per kg of body weight.
    • Administer Hemgenix as an intravenous infusion after dilution with 0.9% normal saline at a constant infusion rate of 500 ml/hour (8 mL/min).

    Mechanism of Action

    Hemgenix (etranacogene dezaparvovec-drlb) is an adeno-associated virus serotype 5 (AAV5) based gene therapy designed to deliver a copy of a gene encoding the Padua variant of human coagulation Factor IX (hFIX-Padua). Single intravenous infusion of Hemgenix results in cell transduction and increase in circulating Factor IX activity in patients with Hemophilia B.

    Side Effects

    Adverse effects associated with Hemgenix may include, but are not limited to, the following:

    • elevated ALT
    • headache
    • blood creatine kinase elevations
    • flu-like symptoms
    • infusion-related reactions
    • fatigue
    • malaise
    • elevated AST

    Hemgenix carries the potential for hepatocellular carcinogenicity in patients with preexisting risk factors (e.g., cirrhosis, advanced hepatic fibrosis, hepatitis B or C, non-alcoholic fatty liver disease (NAFLD), chronic alcohol consumption, non-alcoholic steatohepatitis (NASH), and advanced age).

    Clinical Trial Results

    The FDA approval was based on results from the ongoing HOPE-B trial. The open-label, single-arm study enrolled 54 patients. Following a six-month lead-in period, during which patients continued current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR), patients received a single intravenous administration of Hemgenix at the 2x10^13 gc/kg dose.

    Results from the study demonstrated that Hemgenix allowed patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post infusion. Seven to 18 months post-infusion, the mean adjusted ABR for all bleeds was reduced by 54% compared to the six-

    month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9). In addition, 94% (51 out of 54) of patients treated with Hemgenix discontinued use of prophylaxis and remained free of previous continuous routine prophylaxis therapy.

    Approval Date: 2022-11-01
    Company Name: CSL
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing